Expert healthcare data imagery representing verified HCP research for pharma AI personas and insights agents.

Pharma · · 10 min read

Best pharma market research data providers for AI (2026)

Acumen Editorial · Updated November 22, 2026

Acumen publishes this list. We rank ourselves first and describe every other provider from public sources.

Pharma insights teams now buy research data for two jobs. The first is the classic one: answer a brand question with real HCPs. The second is new: feed AI. Synthetic personas, simulated panels and insights agents are only as good as the primary data underneath them.

The warnings are getting louder. In Pharmaceutical Executive on November 16, 2026, Dan Barton argued that spending on AI in place of primary research leaves brands with gaps, because AI cannot create new behavioral evidence. His line: "AI without fresh evidence amplifies inference, not truth." A month earlier, GLG's Chief Research Officer Chris Howard wrote in HLTH that AI makes fake respondents cheaper and more convincing, and that provenance should be a baseline standard for research providers.

The buyer question has changed: whose data can you trace, defend and put into a model?

How we ranked them

We scored each provider on five criteria that matter when pharma research data has to feed AI as well as decks.

  1. HCP and specialist verification. Are identity, license and specialty checked before anyone answers, and is the method stated publicly?
  2. Provenance. Can each data point be traced to a vetted respondent or expert?
  3. AI readiness. Is the output structured for grounding, training or testing models, not only for a slide?
  4. Validation rigor. Are AI outputs checked against real research and reviewed by humans?
  5. Pharma focus and compliance. Is pharma a core market, and does the provider document how it handles adverse events, privacy and review?

Regulators point the same way. The FDA and EMA guiding principles on good AI practice in drug development, published in January 2026, stress data quality, validation and human oversight, as Barton notes.

The best pharma market research data providers

1. Acumen

What they do: Verified expert data for AI in pharma, healthcare and life sciences: HCP and patient research data, structured expert judgments, rubrics and graded outputs used to ground and evaluate synthetic personas and insights agents.

Best for: Insights, primary market research and commercial analytics teams that need research data an AI system can be built on and tested against.

Verticals and experts: Pharma, healthcare and life sciences only. HCPs, patients and pharma specialists.

Where we fit less well: We are not a full-service tracker shop. Teams that want a large syndicated brand tracker or a standing global panel of their own will pair us with a panel provider.

2. M3 Global Research

What they do: A healthcare market research panel and fieldwork provider, a division of M3 Inc.

Best for: Quantitative HCP studies that need verified respondents across many countries.

Verticals and experts: Healthcare professionals, with research delivered in more than 70 markets and proprietary panels in the Americas, APAC and Europe, per its panel page.

Sourced fact: M3 says prospective members pass three-factor verification of identity, qualifications and specialty under ISO 20252, and that it was the first healthcare panel to verify members with photo ID.

Where it fits less well: Its public pages focus on fieldwork and panel access. Teams that need data shaped for training or testing AI should confirm formats and review steps.

3. GLG

What they do: An expert network offering expert calls, surveys, expert-led research and placements, with a life sciences practice.

Best for: Qualitative depth from senior experts, KOL work and hard-to-reach specialists.

Verticals and experts: Biopharma, medical devices, diagnostics, digital health, lab tools, CROs and more, per its life sciences page.

Sourced fact: In HLTH (October 23, 2026), GLG's Chief Research Officer described GLG Frontier, an effort in which validated experts train and test new models for life sciences teams.

Where it fits less well: Its life sciences page gives no network counts or certifications. Large quantitative samples of practicing HCPs may suit a panel provider better.

4. ZoomRx

What they do: A pharma market research company with HCP and patient panels, tracking studies and AI products, including Sagan Agents and Ferma.

Best for: Brand teams that want primary research and AI message testing from one pharma specialist.

Verticals and experts: Pharma, with oncology, metabolic and CNS named as therapeutic areas, plus HCP and patient panels.

Sourced fact: ZoomRx says its Message Testing agent tests messages against personas grounded in real-world primary and secondary data, benchmarked against 15+ years of its effectiveness data (July 2026).

Where it fits less well: Its personas are built for its own platform. Teams that want raw expert data to train or test their own models should ask about data access.

5. Sermo

What they do: A physician community and insights platform offering quantitative and qualitative research, quick-turn surveys, social listening and drug ratings.

Best for: Fast physician surveys at global scale.

Verticals and experts: Sermo reports 1.3 million HCPs across 150+ countries and 96+ specialties on its market research page.

Sourced fact: The same page cites 600,000+ HCP respondents and 22 million+ answers collected last year.

Where it fits less well: The page says data comes from verified physicians but does not describe the verification method or AI-specific products.

6. ZS

What they do: A consulting and analytics firm that builds simulated panels: synthetic populations of hundreds to thousands of respondents for one decision task.

Best for: Teams that want decision-grade quantitative simulation, built and validated by a consultancy.

Verticals and experts: Pharma commercial and market research.

Sourced fact: ZS reports well-built simulated panels correlated with actual market research at roughly 85% to 95%, versus roughly 50% to 65% for persona-style approaches, in its own benchmarks (July 2026).

Where it fits less well: Simulated panels still need real respondent data to build and validate them. ZS says low-confidence reads need human review.

7. IQVIA

What they do: A large healthcare data, analytics and services company that publishes guidance on synthetic advisory boards.

Best for: Teams already using IQVIA data that want simulated advisory boards before live ones.

Verticals and experts: Pharma and life sciences.

Sourced fact: IQVIA's 2026 white paper describes synthetic advisory boards as hypothesis tools, not replacements, and recommends live boards to validate assumptions before key decisions.

Where it fits less well: The white paper reports no validation study or performance figures. Buyers should ask for evidence on their own therapy area.

How do these providers compare?

ProviderHCP verificationProvenanceAI readinessValidation rigorPharma focus
AcumenCredential and specialty checks per expertPer-item reviewer recordBuilt for grounding, training and testing AIMulti-reviewer adjudicationCore
M3 Global ResearchThree-factor, photo ID, ISO 20252Panel-levelFieldwork outputsNot stated for AICore healthcare
GLGDescribed as verifiedAdvocates per-data-point provenanceModel evaluation effort (GLG Frontier)Expert-ledOne of several industries
ZoomRxProprietary panelsNot statedAI agents on its platformBenchmarked to its own dataCore
SermoDescribed as verifiedNot statedNot statedNot statedCore healthcare
ZSNot applicable (synthetic)Built from respondent dataSimulated panelsBlinded validation vs. real researchCore practice
IQVIANot stated in white paperTraceability recommendedSynthetic advisory boardsLive boards recommendedCore

How do you choose a pharma market research data provider?

Start with the job. If you need a fast read on a message from 300 oncologists, a verified panel is the right buy. If you need data to build or test an AI persona, you need more than answers. You need structured judgments, rationales and a record of who gave them.

Use this checklist on every vendor call:

  • How do you verify identity, license and specialty, and when?
  • Can you trace every data point to a vetted respondent?
  • What formats do you deliver for AI use (JSONL, rubric scores, rationales)?
  • How do you validate synthetic outputs against real research?
  • Who reviews outputs before they reach us, and how are disagreements resolved?
  • How do you handle adverse event reporting and privacy?
  • What happens to our data after the project?

Expect most teams to use two providers: one for live fieldwork and one for AI-grade expert data. Don't ask a fieldwork vendor for training data, or a synthetic tool for fresh evidence.

How Acumen helps

Acumen delivers pharma market research data built for AI. We match verified HCPs, patients and pharma specialists to the task, capture their judgments and rationales in structured form, and adjudicate every item with more than one reviewer. Insights teams use the data to ground synthetic personas, test insights agents against real expert answers and keep a provenance record for compliance review. For the trade-offs between real and synthetic respondents, read primary research vs. synthetic data.

Request a sample dataset Schedule a conversation

FAQ

What are pharma market research data providers?

They are companies that supply primary research data from healthcare professionals, patients and pharma experts. The category spans HCP panels, expert networks, full-service research firms and newer AI-focused data providers. In 2026, buyers increasingly use that data to ground and test synthetic personas and insights agents, not only to answer brand questions.

What is the difference between an HCP panel and an expert network?

An HCP panel recruits large numbers of practicing clinicians for surveys and quantitative studies. An expert network connects you with fewer, often more senior experts for calls, interviews and advisory work. Panels give you sample size; networks give you depth. AI programs often need both, plus structured data a model can use.

Can synthetic personas replace primary market research?

Not on their own. IQVIA calls synthetic advisory boards hypothesis tools and recommends live boards for validation, and ZS says simulated panels need real respondent data and human review of low-confidence reads. Synthetic tools extend fresh evidence. They cannot create it, especially at launch when no history exists.

How should a provider verify HCP respondents?

Ask for identity, license and specialty checks before a respondent participates, and ask how often they are repeated. M3 Global Research, for example, describes three-factor verification with photo ID under ISO 20252. Then ask whether each data point can be traced back to the verified person who supplied it.

What makes market research data AI-ready?

AI-ready data is structured, labeled and traceable. It includes the respondent's answer, their rationale, their specialty and a review record, delivered in formats such as JSONL or rubric scores. That lets teams ground personas, fine-tune models and test agent outputs against real expert answers rather than against assumptions.

How does Acumen work with pharma insights teams?

We scope the decision or AI use case, match verified HCPs, patients or pharma specialists, and deliver adjudicated, structured data with full provenance. Teams start with a pilot dataset and a quality report, then scale on a recurring cadence. Request a sample dataset to see the format before you commit.

Related links

Pharma market research data

Primary research vs. synthetic data

From the Acumen archive. Explore expert data and Healthcare & Pharma.

← Back to Insights